PAX8 Protein & Mesothelioma

PAX8 is considered a negative marker for mesothelioma. Checking for this protein helps doctors ensure a tumor is mesothelioma and not another type of cancer. However, a rare subtype called well-differentiated papillary mesothelioma often does express PAX8.

Written By

Edited By

Medical Review By

This page features: 11 cited research articles

The PAX8 protein is a transcription factor, meaning it attaches to certain areas of DNA. Transcription factors turn genes on and off, helping to regulate how cells in the body work. The PAX8 protein is important to the formation and functioning of the kidney and the thyroid gland.

The PAX8 protein is made by the PAX8 gene, also known as “paired box gene 8.”

Different parts of the body use different types of proteins. When doctors diagnose cancer, they can look for PAX8 and other proteins to figure out where the cancer originally developed. This technique of using proteins as diagnostic clues is called immunohistochemistry.

Doctors must determine exactly what type of cancer is present to make sure the patient gets the correct treatment.

The International Mesothelioma Interest Group’s 2012 guidelines for mesothelioma diagnosis list some of the most common proteins doctors check for. These proteins are called immunohistochemical markers.

PAX8 as an Immunohistochemical Marker for Mesothelioma

PAX8 is considered a negative marker for mesothelioma. This means mesothelioma cancer cells usually do not test positive for PAX8.

PAX8 is a common marker for kidney cancer, thyroid cancer and cancers of the female reproductive system. When doctors suspect mesothelioma, it is useful to double-check for PAX8 to make sure the tumor is not actually another type of cancer.

For example, a tumor on the surface of a lung could be pleural mesothelioma or kidney cancer that has spread to the chest. A tumor in the abdomen could be peritoneal mesothelioma or metastasized ovarian cancer. In these examples, checking for PAX8 would provide a vital clue.

However, there is one type of mesothelioma that often expresses PAX8. This variant is called well-differentiated papillary mesothelioma (WDPM), and it is extremely rare. Unlike other types of mesothelioma, WDPM is usually benign.

A 2018 study published in Human Pathology reported more than half of WDPM cases test positive for PAX8. Other techniques must be used to distinguish WDPM from low-grade gynecologic lesions.

The process of mesothelioma diagnosis is highly complex, and it requires the expertise of an experienced specialist.

Want Answers About Mesothelioma?

We Can Help
Asbestos.com Mesothelioma Packet

Get Your Free Mesothelioma Guide

Order Yours Now

Need Financial Help for Your Mesothelioma?

Learn More

Get Answers to Your Mesothelioma Questions

Get Your Free Mesothelioma Guide

Find Financial Help for Your Mesothelioma

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?


Karen Selby, RN and Patient Advocate at The Mesothelioma Center

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators. Read More

Reviewed by placeholder

Medical Review By

Last Modified August 1, 2018
Sources
  1. U.S. National Library of Medicine. (2018, April 17). PAX8 gene.
    Retrieved from: https://ghr.nlm.nih.gov/gene/PAX8
  2. Xing, D. et al. (2018, February). Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Retrieved from: https://www.sciencedirect.com/science/article/pii/S004681771730463X
  3. Tandon, R. et al. (2018). Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
    Retrieved from: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0092-OA?code=coap-site
  4. Chapel, D. et al. (2017, December). PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28877056
  5. Nakamura, K. et al. (2017, January). The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244981/
  6. Husain, A. et al. (2013, May). Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/22929121
Chat live with a patient advocate now loading spinner